Pheniramine (maleate)

Pheniramine (Prophenpyridamine; Tripoton) maleate is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine maleate displays antitumor effect and induces leukemia cells apoptosis. Pheniramine maleate is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects[1][2][3][4].

Product Specifications

CAS Number

[132-20-7]

Product Name Alternative

Prophenpyridamine (maleate) ; Tripoton (maleate)

UNSPSC

12352005

Hazard Statement

H302

Target

Apoptosis; Histamine Receptor

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Pheniramine-Maleate.html

Purity

99.94

Solubility

H2O : ≥ 38 mg/mL

Smiles

CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2.O=C(O)/C=C\C(O)=O

Molecular Formula

C20H24N2O4

Molecular Weight

356.42

Precautions

H302

References & Citations

[1]Sharma A, et al. Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view. Curr Drug Metab. 2003 Apr;4 (2) :105-29.|[2]Brown RD, et al. Alpha 1-adrenergic and H1-histamine receptor control of intracellular Ca2+ in a muscle cell line: the influence of prior agonist exposure on receptor responsiveness. Mol Pharmacol. 1986 Jun;29 (6) :531-9.|[3]Jangi SM, et al. Apoptosis of human T-cell acute lymphoblastic leukemia cells by diphenhydramine, an H1 histamine receptor antagonist. Oncol Res. 2004;14 (7-8) :363-72.|[4]Hung CH, et al. Spinal anesthesia with diphenhydramine and pheniramine in rats. Eur J Pharmacol. 2011 Dec 30;673 (1-3) :20-4.